Continuous glucose monitoring system maker Senseonics has won FDA approval for its Eversense E3, which can be used to measure glucose levels in adults with diabetes for up to six months.
The system works using a sensor that is implanted just under the skin by a healthcare provider. A transmitter worn over the sensor, on top of the skin, receives glucose data, provides vibratory alerts and...
This morning Swiss company Ascensia Diabetes Care, maker of connected glucose meters, unveiled its new diabetes management and analytics platform, dubbed GlucoContro.online.
The tool is able to work with the company's existing Contour glucose meters and can capture data directly from the Contour Diabetes app or Contour cloud. The new platform is cloud-based and lets users open in their browsers....
Continuous glucose monitoring (CGM) system-maker Senseonics has cut a deal with Ascensia Diabetes Care and its parent company, PHC Holdings, outlining commercialization and distribution of the Eversense product line over the next few years.
According to the companies, Ascensia now holds exclusive global distribution rights for the Eversense, Eversense XL and future CGMs. The duration of the...
Ascensia Diabetes Care, the Swiss tech company originally formed a few years ago from a merger of Bayer Health’s diabetes division and Panasonic Healthcare, is officially moving into the CGM space via a partnership with Huzhou, China-based Zhejiang POCTech.
In the short term, the partnership will put an Ascensia-branded version of POCTech’s CE-Marked CGM in several markets by the end of the year...
Ascensia Diabetes Care’s Contour Diabetes app — a mobile tool to monitor trends in blood glucose levels that connects to the Contour Next One glucometer — has received yet another update. As of Monday, iPhone users can transfer blood glucose and carbohydrate data from their app to records kept within the Apple Health platform.
After opting in, data collected through Ascensia’s app will...
What happened
In a triple-blinded, multisite, independent study, researchers have found that only one third of commercially available FDA-cleared blood glucose meters in the United States could consistently perform to an accuracy standard close to, but actually more lenient than, the FDA’s. Of the 18 BCGs tested, only six were consistently accurate in each of three test sites. Five were compliant...
This weekend saw the kickoff of the American Diabetes Association’s 78th annual conference, and with it a slew of new data from diabetes management players. The meeting included presentation on studies covering a range of technologies, such as continuous glucose monitors, insulin pumps, apps, and other digital-backed management strategies.
Among the studies highlighted by the association was an...
This morning Ascensia Diabetes Care launched the latest version of its Contour Diabetes app in the United States. The upgraded app will offer users a new feature, called My Patterns, which will give personalized feedback and coaching to users.
“The My Patterns feature on the new Contour Diabetes app represents a real advance in the use of data for diabetes management,” Michael Kloss, CEO at...
Innovators compete. Ascensia Diabetes Care has announced the six finalists in its innovation competition, which is aimed at finding digital platforms to support Type 2 diabetes management. The competition included 116 submissions from North America, Asia, and Europe. The six finalists are: Foodient by Whisk, an artificial intelligence-powered dietary app that connects to large grocery retailers,...
Today Ascensia Diabetes Care UK launched the latest version of its Contour Diabetes app, a tool that helps people self-manage their diabetes, in the UK and Ireland. The app is designed to connect to the company’s Contour One Next blood glucose meter.
“This latest upgrade to the Contour Diabetes app provides patients with a smarter tool that can help to make the self-management of their diabetes...
